Sage Therapeutics (SAGE) Expected to Announce Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Tuesday, April 29th. Analysts expect Sage Therapeutics to post earnings of ($1.00) per share and revenue of $14.12 million for the quarter.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. On average, analysts expect Sage Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sage Therapeutics Price Performance

NASDAQ:SAGE remained flat at $7.79 during midday trading on Friday. The company had a trading volume of 1,020,475 shares, compared to its average volume of 1,220,872. The company's 50 day simple moving average is $7.52 and its 200-day simple moving average is $6.75. The stock has a market capitalization of $478.94 million, a P/E ratio of -1.18 and a beta of 0.48. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $14.71.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Bank of America assumed coverage on Sage Therapeutics in a report on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price objective for the company. Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a report on Wednesday, February 12th. Canaccord Genuity Group lowered their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Wednesday, February 12th. HC Wainwright reissued a "neutral" rating and set a $12.00 price objective (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Wedbush reissued a "neutral" rating and issued a $6.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics currently has an average rating of "Hold" and an average price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.